U.S. stock futures slightly higher after Christmas holiday

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/21/2026

1. INTC
2. DSX
3. GNK
4. TTEC
5. DAL
6. AWK
7. SPCX
8. III
9. TEVA
10. FCLI

Go back to U.S. stock futures slightly higher after Christmas holiday

Ionis Pharmaceuticals (IONS) PT Raised to $68 at BMO Capital

December 28, 2016 3:55 PM EST

BMO Capital analyst Do Kim reiterated an Outperform rating and rasied his price target on Ionis Pharmaceuticals (NASDAQ: IONS) to $68.00 (from $61.00) as the firm's Spinraza estimates increase to reflect a faster ramp based on the broad approval and a higher price point... More

Ionis Pharmaceuticals (IONS) Spinraza Approval Expected But a 'Major Positive', Laidlaw Says; PT Up To $65

December 27, 2016 9:31 AM EST

Laidlaw analyst Yale Jen reiterated a Buy rating and raised its price target on Ionis Pharmaceuticals (NASDAQ: IONS) to of $65.00 (from $59.00) announced the FDA approved Spinraza as a spinal muscular atrophy (SMA) treatment in pediatric and adult (late-onset) patients. IONS earned a... More

Needham & Company Reiterates Buy on Ionis Pharmaceuticals (IONS) Following FDA Approval

December 27, 2016 9:26 AM EST

Needham & Company analyst Chad Messer reiterated a Buy rating and $64 price target on Ionis Pharmaceuticals (NASDAQ: IONS) and partner Biogen were granted FDA approval for SPINRAZA (nusinersen), a treatment for spinal muscular atrophy. SPINRAZA will have a broad label including both children and adults... More